Market Place
Sourcing Support
Largest Sarcoma Study Shows Signatera`s Excellent Performance
05 May 2025 //
BUSINESSWIRE
Natera to Report its First Quarter Results on May 8, 2025
01 May 2025 //
BUSINESSWIRE
DEFINE-HT: Prospera Heart Outperforms Biopsy in Graft Risk
29 Apr 2025 //
BUSINESSWIRE
Natera Launches Signatera Genome MRD Test
24 Apr 2025 //
BUSINESSWIRE
Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting
22 Apr 2025 //
BUSINESSWIRE
Natera Enrolls First Patients In HEROES Trial For HER2+ Breast Cancer
10 Mar 2025 //
BUSINESSWIRE
Natera`s Ph 3 CALGB/SWOG 80702 Trial Results In Colorectal Cancer
25 Jan 2025 //
BUSINESSWIRE
Guardant prevails over Natera in false advertising case
26 Nov 2024 //
FIERCE PHARMA
Natera Completes Signatera™ Analysis from CALGB/SWOG 80702 Trial
12 Nov 2024 //
BUSINESSWIRE
Natera To Present New Signatera CRC Data At ESMO
08 Sep 2024 //
BUSINESSWIRE
Natera Announces DECIPHER: A Ph II, Single-Arm Adjuvant Trial Gastro Cancer
27 Jun 2024 //
BUSINESSWIRE
Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference
23 May 2024 //
BUSINESSWIRE
Natera to Report its First Quarter 2024 Results on May 9
01 May 2024 //
BUSINESSWIRE
Natera Announces Positive Analysis from the Randomized Ph III IMvigor011 Trial
05 Apr 2024 //
BUSINESSWIRE
Natera and Alliance Trials: A Randomized, Ph II/III Trial in Urothelial Cancer
01 Apr 2024 //
BUSINESSWIRE
Natera to Participate in March Investor Conferences
29 Feb 2024 //
BUSINESSWIRE
Medicare Extends Coverage of Natera’s Signatera™ MRD Test
26 Feb 2024 //
BUSINESSWIRE
Natera wins first phase of patent trial over CareDx genetic tests
26 Jan 2024 //
REUTERS
Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment
06 Dec 2023 //
BUSINESSWIRE
Natera Announces Real-World Data Collaboration with Merck
14 Nov 2023 //
BUSINESSWIRE
Natera Announces Randomized, Phase III Trial in Early-Stage Breast Cancer
08 Nov 2023 //
BUSINESSWIRE
Updated Data from CIRCULATE-Japan Presented at ESMO 2023
22 Oct 2023 //
BUSINESSWIRE
Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera
14 Sep 2023 //
BUSINESSWIRE
Natera to Participate in Canaccord Genuity 43rd Annual Growth Conference
02 Aug 2023 //
BUSINESSWIRE
Court Issues Favorable Ruling for Natera in False Advertising Trial Against CareDx
17 Jul 2023 //
BUSINESSWIRE
Natera wins $19 mln US verdict from ArcherDX in cancer-detection patent case
15 May 2023 //
REUTERS
Natera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility
08 May 2023 //
BUSINESSWIRE
Natera Announces New Signatera™ MRD Data at 2023 AACR Annual Meeting
14 Apr 2023 //
BUSINESSWIRE
New Publication Demonstrates Utility of Natera’s Signatera™ Test in Melanoma
22 Mar 2023 //
BUSINESSWIRE
Natera Announces Commercial Payor Coverage for Signatera™
02 Mar 2023 //
BUSINESSWIRE
Foundation Medicine and Natera Announce the Launch of FoundationOneTracker
08 Jan 2023 //
BUSINESSWIRE
Natera Announces Publication of Study Validating Signatera`s Ability
09 Dec 2022 //
BIONJ
New Publication Validates Performance of Natera’s Signatera MRD Test
06 Oct 2022 //
NATERA
CareDx-Initiated IP Litigation Against Natera, Natera Now Drops 1 of 2 Patents
17 May 2022 //
GLOBENEWSWIRE
Law firm files class action against pharma company Natera
03 May 2022 //
REUTERS
CareDx Wins $44.9M in Damages in False Advertising Trial Against Natera
14 Mar 2022 //
GLOBENEWSWIRE
Natera shares tumble after short-seller alleges deceptive billing practices
10 Mar 2022 //
ENDPTS
Natera presents +ve data from CIRCULATE-Japan study of tumour-informed MRD test
25 Jan 2022 //
PHARMABIZ
Natera Launches Prospera Lung Transplant Assessment Test
18 Oct 2021 //
BIOSPACE
Natera Launches Prospera Kidney with Quantification
09 Sep 2021 //
BIOSPACE
Natera and BGI Genomics Launch of the BGI/Natera Signatera Assay
26 Jun 2021 //
PR NEWSWIRE
Natera`s Signatera MRD test receives US FDA two new Breakthrough Device
24 Mar 2021 //
PHARMABIZ
Natera and Genentech Initiate Phase III Trial Using Signatera™
10 Mar 2021 //
BIOSPACE
New Signatera™ Data to be Presented at the 2020 ESMO Phase III IMvigor010 Trial
08 Dec 2020 //
PRNEWSWIRE
Natera Announces Prospective Randomized Clinical Trial to Evaluate Palbociclib
02 Oct 2020 //
PRNEWSWIRE
Natera Fights Illumina`s Bid To Invalidate DNA Testing Patent
17 Sep 2020 //
LAW360
Natera Announces Pricing of Follow-On Offering
11 Sep 2020 //
PRNNEWSWIRE
